Q4 2021 13F Combination Report, New Holdings, Stock Holdings
Signature - Title
Ronald Fisher-Dayn - Managing Partner and Chief Compliance Officer
Location
Toronto, Ontario, Canada
Holdings as of
December 31, 2021
Value $
$50.7M
Num holdings
1
Date filed
5/17/2022, 09:50 AM
Description
Request for Confidential Treatment (2/14/2022): Confidential Treatment Expired on 5/16/2022. The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as
of the end of the calendar quarter for which the report is filed, and the total market value. The market value
column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in
accounts.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
This filing lists securities holdings reported on the form 13F filed on 02-14-2022 pursuant to a request for confidential treatment and for which confidential treatment expired on 05-16-2022.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Ronald Fisher-Dayn
MANAGING DIRECTOR, LEGAL & REGULATORY
NY, New York
5/16/2022
THIS FILING LISTS SECURITIES HOLDINGS REPORTED ON THE FORM 13F FILED ON February 14, 2022 PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FOR WHICH CONFIDENTIAL TREATMENT WILL EXPIRE ON MAY 16, 2022.
List of Other Managers Reporting for BROOKFIELD Corp /ON/:
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.